Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemiaMasamichi Mori, Sadao Kuromitsu|Investigational New Drugs|2017Cited by 254
Identification of a novel oncogenic mutation of FGFR4 in gastric cancerT. Futami, Sadao Kuromitsu|Scientific Reports|2019Cited by 16